These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 34129749)

  • 1. Localized cutaneous reaction to an mRNA COVID-19 vaccine.
    Edriss M; Farshchian M; Daveluy S
    J Cosmet Dermatol; 2021 Aug; 20(8):2380-2381. PubMed ID: 34129749
    [No Abstract]   [Full Text] [Related]  

  • 2. Late-onset cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine in an immunocompromised patient.
    Weinstock-Guttman B; Jakimovski D
    Mult Scler; 2021 Dec; 27(14):2291-2292. PubMed ID: 34100306
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinicopathological features of cutaneous reactions after mRNA-based COVID-19 vaccines.
    Tihy M; Menzinger S; André R; Laffitte E; Toutous-Trellu L; Kaya G
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2456-2461. PubMed ID: 34459036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Surveillance of COVID-19 mRNA Vaccines Through the Vaccine Safety Datalink.
    Blumenthal KG; Phadke NA; Bates DW
    JAMA; 2021 Oct; 326(14):1375-1377. PubMed ID: 34477809
    [No Abstract]   [Full Text] [Related]  

  • 5. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. 'COVID-arm': a clinical and histological characterization.
    Fernandez-Nieto D; Hammerle J; Fernandez-Escribano M; Moreno-Del Real CM; Garcia-Abellas P; Carretero-Barrio I; Solano-Solares E; de-la-Hoz-Caballer B; Jimenez-Cauhe J; Ortega-Quijano D; Fernandez-Guarino M
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e425-e427. PubMed ID: 33783873
    [No Abstract]   [Full Text] [Related]  

  • 6. Livedoid skin reaction to 2nd dose of mRNA Covid-19 vaccine.
    Girolami I; Eisendle K; Kluge RW; Hanspeter E; Eccher A; Vizziello L; Zampieri P; Mazzoleni G
    Pathologica; 2022 Aug; 114(4):322-325. PubMed ID: 36136900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PEG skin testing for COVID-19 vaccine allergy.
    Stone BD
    J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1765. PubMed ID: 33838847
    [No Abstract]   [Full Text] [Related]  

  • 8. How important is the second dose of the COVID-19 mRNA vaccine?
    Liu AY
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2537. PubMed ID: 34112480
    [No Abstract]   [Full Text] [Related]  

  • 9. Skin ulcer at the injection site of BNT162b2 mRNA COVID-19 vaccine.
    Aoki N; Saruta Y; Tanaka S; Nakajima R; Sano H; Sano S
    J Dermatol; 2021 Dec; 48(12):e596-e597. PubMed ID: 34545609
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    Skowronski DM; De Serres G
    N Engl J Med; 2021 Apr; 384(16):1576-1577. PubMed ID: 33596348
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.
    Absalon J; Koury K; Gruber WC
    N Engl J Med; 2021 Apr; 384(16):1578. PubMed ID: 33596351
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
    Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
    Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
    [No Abstract]   [Full Text] [Related]  

  • 13. Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients.
    Yanay NB; Freiman S; Shapira M; Wishahi S; Hamze M; Elhaj M; Zaher M; Armaly Z
    Kidney Int; 2021 Jun; 99(6):1496-1498. PubMed ID: 33887318
    [No Abstract]   [Full Text] [Related]  

  • 14. Delayed cutaneous reactions after the administration of mRNA vaccines against COVID-19.
    Juárez Guerrero A; Domínguez Estirado A; Crespo Quirós J; Rojas-Pérez-Ezquerra P
    J Allergy Clin Immunol Pract; 2021 Oct; 9(10):3811-3813. PubMed ID: 34293500
    [No Abstract]   [Full Text] [Related]  

  • 15. First-Dose mRNA COVID-19 Vaccine Allergic Reactions: Limited Role for Excipient Skin Testing.
    Wolfson AR; Robinson LB; Li L; McMahon AE; Cogan AS; Fu X; Wickner P; Samarakoon U; Saff RR; Blumenthal KG; Banerji A
    J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3308-3320.e3. PubMed ID: 34166844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Perimyocarditis Following First Dose of mRNA Vaccine Against COVID-19.
    Vollmann D; Eiffert H; Schuster A
    Dtsch Arztebl Int; 2021 Aug; 118(31-32):546. PubMed ID: 34515024
    [No Abstract]   [Full Text] [Related]  

  • 17. Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2.
    Blumenthal KG; Freeman EE; Saff RR; Robinson LB; Wolfson AR; Foreman RK; Hashimoto D; Banerji A; Li L; Anvari S; Shenoy ES
    N Engl J Med; 2021 Apr; 384(13):1273-1277. PubMed ID: 33657292
    [No Abstract]   [Full Text] [Related]  

  • 18. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
    Roest S; Hoek RAS; Manintveld OC
    N Engl J Med; 2021 May; 384(20):1968-1970. PubMed ID: 33882226
    [No Abstract]   [Full Text] [Related]  

  • 19. Accelerate Coronavirus Disease 2019 (COVID-19) Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines.
    Plotkin SA; Halsey N
    Clin Infect Dis; 2021 Oct; 73(7):1320-1321. PubMed ID: 33502467
    [No Abstract]   [Full Text] [Related]  

  • 20. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply.
    Barda N; Dagan N; Balicer RD
    N Engl J Med; 2021 May; 384(20):1970. PubMed ID: 33882227
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.